Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

@article{Mueller2007ExpressionOA,
  title={Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells},
  author={Tina Mueller and Christoph Uherek and Guitta Maki and Kai Uwe Chow and Annemarie Schimpf and H Klingemann and Torsten Tonn and Winfried S. Wels},
  journal={Cancer Immunology, Immunotherapy},
  year={2007},
  volume={57},
  pages={411-423}
}
Despite the clinical success of CD20-specific antibody rituximab, malignancies of B-cell origin continue to present a major clinical challenge, in part due to an inability of the antibody to activate antibody-dependent cell-mediated cytotoxicity (ADCC) in some patients, and development of resistance in others. Expression of chimeric antigen receptors in effector cells operative in ADCC might allow to bypass insufficient activation via FcγRIII and other resistance mechanisms that limit natural… CONTINUE READING